The company also reported pharmacokinetic data at NLA showing no drug-drug interaction between Vascepa and cholesterol drug Lipitor (atorvastatin, Pfizer Inc.) or anticoagulant warfarin

Pfizer Inc., of New York, said its Centers for Therapeutic Innovation (CTI) has expanded into the development of small-molecule drug candidates through a partnership with the University of California, San Francisco (UCSF

Pfizer Inc., of New York, said it intends to split off its remaining interest in Zoetis Inc., of Madison, N.J., the former animal health unit that recently completed its initial public offering

In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies

Addex Therapeutics SA, of Geneva, said regulatory authorities in the Netherlands gave approval to start in the first half of this year a Phase I study of ADX71441, a GABA-B receptor positive allosteric modulator, for Charcot-Marie-Tooth1A (CMT1A) neuropathy and other disease indications...for the Brisbane, Australia-based company's Diversity Scanning Array (DSA) and Versatile Assembly on Stable Templates (VAST) technologies in a deal worth up to $240 million in milestones, plus other payments

Inc., of Whitehouse Station, N.J., and Pfizer Inc., of New York, have entered a worldwide (except Japan) collaborative agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose co-transporter (SGLT2) inhibitor being evaluated for the treatment of Type II diabetes

The product will be marketed in those countries by Pfizer Inc., the

Pfizer Inc., of New York, said the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for Xeljanz (tofacitnib citrate) for the treatment of adults with moderate to severe active rheumatoid arthritis

Merck KGgA, of Darmstadt, Germany, reported that a collaboration agreement between its subsidiary, EMD Serono Inc., and Pfizer Inc., of New York, inked in July 2002 for the co-promotion of multiple sclerosis drug Rebif (interferon beta-1a) extends until Dec. 31, 2015, according to an appellate court ruling

Merck KGgA, of Darmstadt, Germany, reported that a collaboration agreement between its subsidiary, EMD Serono Inc., and Pfizer Inc., of New York, inked in July 2002 for the co-promotion of multiple sclerosis drug Rebif (interferon beta-1a) extends until Dec. 31, 2015, according to an appellate court ruling

Pfizer Inc., of New York, said its palbociclib (PD-0332991), an oral and selective inhibitor of cyclin-dependent kinases 4 and 6, received breakthrough therapy designation by the FDA for the potential treatment of patients with breast cancer

Tetragenetics Inc., of Cambridge, Mass., said it inked a deal with an option for an exclusive license with New York-based Pfizer Inc

Pfizer Inc., of New York, said the European Commission granted conditional marketing authorization for Bosulif (bosutinib) for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome-positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitors and for whom Gleevec (imatinib, Novartis AG), Tasigna (nilotinib, Novartis AG) and Sprycel (dasatinib, Bristol-Myers Squibb Co.) are not considered appropriate

KineMed Inc., of Emeryville, Calif., said it renewed a nonexclusive research collaboration with Pfizer Inc., of New York, to advance approaches for treating metabolic disease, in particular Type II diabetes

Pfizer Inc., of New York, said Japanese regulators approved Xeljanz (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis who have had an inadequate response to existing therapies

Pfizer Inc., of New York, and Protalix BioTherapeutics Inc., of Carmiel, Israel, said the Brazilian National Health Surveillance Agency (Agencia Nacional de Vigilancia Sanitaria, or ANVISA) granted regulatory approval to Uplyso (alfataliglicerase) as long-term enzyme replacement therapy for adults with a confirmed diagnosis of Type I Gaucher disease

With this new approval, Stivarga is intended to be used in patients whose GIST cancer cannot be removed by surgery or is metastatic and no longer responding to Gleevec (imatinib, Novartis AG) and Sutent (sunitinib, Pfizer Inc.), two other FDA-approved drugs to treat GIST

Pursuant to the terms, each of the company's ordinary shares, including shares represented by American depositary shares (ADS), will be cancelled in exchange for the right to receive $2.20 in each per share, or $15.40 per ADS...Due to the oversubscription, the closing unit price was set at NIS3.544 per unit

OxOnc Development LP, of Princeton, N.J., said it entered a co-development agreement with Pfizer Inc., of New York, to conduct a pivotal trial of Pfizer's Xalkori (crizotinib) in patients with non-small-cell lung cancer harboring a ROS1 (c-ros) gene rearrangement